Gender specific tumour pharmacology--from kinetics to genetics.

Robert M Mader

Journal: Wiener medizinische Wochenschrift (1946) 2007;156(19-20):545-8

PMID: 17103292

Abstract

Gender specific tumour pharmacology only started to awake interest in the mid-90s. The most advanced studies include gender specific fluoropyrimidine pharmacokinetics and basic levels of pharmacogenomics, but most pharmacogenetic questions have remained unanswered. Considering polymorphisms of relevant drug converting enzymes such as folate reductase, cytochrome P450 dependent oxidases, and UDP-glucuronyltransferase, we have to rely more on hypotheses than on facts. This very limited knowledge base on gender specific tumour pharmacology urgently needs to be expanded in randomized clinical trials, because only clinical evidence will provide the sound base necessary for its implementation in oncologic therapies.

Address: Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria. [email protected]

DOI: 10.1007/s10354-006-0344-z

Link outs

Subscription / membership required

Full Text Sources:

https://dx.doi.org/10.1007/s10354-006-0344-z

MeSH Terms: Antimetabolites, Antineoplastic, Antineoplastic Agents, Cytochrome P-450 Enzyme System, Cytochrome Reductases, Female, Fluorouracil, Glucuronosyltransferase, Humans, Male, Neoplasms, Pharmacogenetics, Polymorphism, Genetic, Sex Characteristics, Tetrahydrofolate Dehydrogenase